

Цитопротектор «Мексикор» в лечении церебральной ишемии: анализ клинического опыта применения

e-mail: afirs67@mail.ru

A. A. FIRSOV

SBEI WE «Mordovia state university n. a. N. P. Ogarev,» Saransk

FSAEI HE «Peoples' friendship university of Russia», «Institute of innovative educational programs in health care», Moscow

Cytoprotector Mexicor in the treatment of cerebral ischemia. Analysis of clinical experience

Firsov Anatoly A.

MD, PhD, assistant professor of department of geriatrics and organization of gerontology research FSAEI HE

«Peoples' friendship university of Russia», «Institute of innovative and educational programs in health care»

e-mail: afirs67@mail.ru

Summary: it is showed the results of the study of Mexicor efficiency in acute cerebrovascular insufficiency. A total of 80 patients in the two groups of 40 people who received Mexicor parenterally for 14 days after ischemic stroke were examined. It were obtained statistically significant evidences of effectiveness Mexicor in case of regression of neurological deficit, timing and extent of recovery of cognitive function, reduce the degree of patient disability. Mexicor effectiveness in 40 patients with chronic ischemia of the brain is also evaluated. It was found a positive effect of the drug on the severity of cognitive impairment with circulatory encephalopathy.

Keywords: mexicor, ischemic stroke, circulatory encephalopathy, cognitive impairment.

(...);

-
-
-

« ... »

« ... »

(... , 2009).

1. ...

(...)

2-3-

(... , 2003;

... , 2002, 2006).

(... , 2009; ... , 2009).

(...)

(... , 2002).

(... , 2005). « ... »

3 : 2

(...)

300

7-

3

2

2

200


2

40

(...)

1- , 8- 15-

: Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), «10», «




8-

A

(4,3±0,11; 3,1±0,14 6,3±0,05). 15-

69,4% (- 73,4%,

39,2%.



Mini-Mental State Examination (MMSE).


2.

MMSE
31,1% 32,2%,
13,9%.

	1-	8-	15-
	3,8±0,18	5,0±0,12*	6,7±0,14**
	3,7±0,19	5,6±0,21*	6,9±0,18**
	3,7±0,11	4,5±0,14	5,5±0,09


* – <0,005, ** <0,0005

4,4±0,09 2,3±0,08 6,7±0,12
(≥7) 17- (42,5%)
, 24- (60%) 10-
(25%) –



* – <0,005, ** <0,0005

7- (17,5%) (3).
« »



* – <0,005, ** <0,0005

« »
2
50%, –81%, 2 3,2

1,5
(7,1±0,08 10,5±0,11).
69%: 7,2±0,09 2,2±0,05.
65,7%.
8- 15-
4,4±0,09 2,3±0,08 6,7±0,12

1.
2.
3.
4.
5.
900
450
7- 200 2 2
7- 2

2.

®

()

« »
7,9 (62,6 54,7),

7-

5,1 56,6 .

« »

0,5

65 , 15%
2020-

« » 5- 9-

., 2005).

(

10

« »

« »

1. « »

®

(« »). : , 2001, . 34.

2. « » (

40

, Consilium medicum (

II

».

, 2004, . 6, 8, . 598-601.

3. « »

4. « » , 2005, . 41-49.

: Mini-Mental State Examination (MMSE),

« » , 2005, . 49-66.

« » , «10 » « » .

5. « » , 2001.

6. « » :

(20)

1 (5) 3 1

7. « » , 2005, 6, . 1-5 13.

(50)

20 ,

8. « » , 1,

« » 2 (100)

9. « » , 2005, . 25.

38-43.

10. « » , 2001, . 261-266.

« » 8 10

MMSE >24 (24

11. « » , 2003, 9, . 20-25.

), 2 10

21,0%

SE

10,4 %

10. « » , 2001, . 261-266.

25% (4,8 6) ,
44,7% (4,7 6,8) .

21,8% (3,2 3,9

11. « » , 2003, 9, . 20-25.

), 35,5% (3,1 4,2) .

« » , 1995, . 1, . 9-29.